For Q4 2025, Wave Life Sciences generated revenue of 17244000 and reported a net loss of 53179000, driven by higher research and development and general and administrative expenses compared to the prior year quarter.

Wave Life Sciences delivered improved financial performance in Q3 2025 with increased revenue and reduced net loss. The company advanced key clinical programs, particularly in obesity and alpha-1 antitrypsin deficiency, and maintained a strong cash position.

Wave Life Sciences reported a net loss of $46.878 million for the first quarter of 2025, compared to a net loss of $31.558 million in the prior year quarter. Revenue decreased to $9.175 million from $12.538 million in the same period last year. The company ended the quarter with $243.075 million in cash and cash equivalents, with a runway expected into 2027.

Wave Life Sciences delivered an impressive Q4 2024, with revenue surging to $83.7 million from $29.1 million in the prior year quarter. The company reported a net income of $29.3 million, marking a turnaround from a net loss of $16.3 million a year ago. Increased research and development investments fueled clinical advancements across multiple programs, positioning Wave for continued momentum in 2025.

Wave Life Sciences reported positive clinical updates across DMD and AATD, achieved first-ever RNA editing in humans, and advanced its pipeline. The company's cash runway is expected into 2027.

Wave Life Sciences announced positive clinical data from the Phase 1b/2a SELECT-HD study of WVE-003 and initiated dosing in the RestorAATion-2 clinical trial of WVE-006 in AATD patients. The company's cash and cash equivalents were $154.0 million as of June 30, 2024. Revenue was $19.7 million, and net loss was $32.9 million for the second quarter of 2024.

Wave Life Sciences reported a net loss of $31.6 million for the first quarter of 2024, compared to a net loss of $27.4 million for the first quarter of 2023. Cash and cash equivalents were $180.9 million as of March 31, 2024. Revenue was $12.5 million for the first quarter of 2024, as compared to $12.9 million in the first quarter of 2023.

Wave Life Sciences reported its Q4 2023 financial results, with revenue increasing significantly due to collaborations with GSK and Takeda. The company's cash and cash equivalents totaled $200.4 million, expected to fund operations into Q4 2025. A net loss of $16.3 million was reported for the quarter, an improvement over the prior year.

Wave Life Sciences reported a net income of $7.3 million for the third quarter of 2023, driven by increased revenue from collaborations. The company is advancing its RNA editing and therapeutic programs, including WVE-006, WVE-N531, and WVE-003, and expanding its pipeline with a new GalNAc-siRNA INHBE program. Cash and cash equivalents were $140 million as of September 30, 2023, expected to fund operations into 2025.

Wave Life Sciences reported a net loss of $21.1 million for the second quarter of 2023, driven by revenue recognized under the collaboration with GSK. The company's cash and cash equivalents totaled $173.0 million as of June 30, 2023, expected to fund operations into 2025.

Wave Life Sciences reported a net loss of $27.4 million for the first quarter of 2023. The company's cash and cash equivalents totaled $207.6 million as of March 31, 2023, expected to fund operations into 2025.

Wave Life Sciences reported a net loss of $43.7 million in the fourth quarter of 2022. They entered into a strategic collaboration with GSK and are advancing their RNA editing and other platform capabilities.

Wave Life Sciences reported a net loss of $39.0 million with revenue of $0.3 million in the third quarter of 2022. The company's cash, cash equivalents, and short-term investments totaled $122.0 million as of September 30, 2022.

Wave Life Sciences reported a net loss of $41.3 million and revenue of $0.4 million for the second quarter of 2022. The company's cash, cash equivalents, and short-term investments totaled $148.2 million as of June 30, 2022, which is expected to fund operating and capital expenditure requirements to the end of 2023.

Wave Life Sciences reported revenue of $1.8 million and a net loss of $37.8 million in the first quarter of 2022. The company's cash, cash equivalents, and short-term investments totaled $111.7 million as of March 31, 2022.

Wave Life Sciences reported a net loss of $34.8 million in the fourth quarter of 2021, with revenue earned under the Takeda Collaboration at $1.8 million. Research and development expenses were $25.8 million, while general and administrative expenses were $12.1 million. The company's cash and cash equivalents totaled $150.6 million as of December 31, 2021, expected to fund operations into the second quarter of 2023.

Wave Life Sciences reported a net loss of $6.2 million for the third quarter of 2021, with revenue of $36.4 million. The company highlighted advancements in its RNA editing capabilities and the initiation of dosing in three clinical trials.

Wave Life Sciences reported a net loss of $38.8 million in the second quarter of 2021. The company's cash and cash equivalents totaled $143.8 million as of June 30, 2021, and expects existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.

Wave Life Sciences reported a net loss of $42.5 million for the first quarter of 2021, compared to a net loss of $47.5 million for the same period in 2020. Research and development expenses were $33.4 million, and general and administrative expenses were $10.1 million. The company ended the quarter with $148.5 million in cash and cash equivalents.

Wave Life Sciences reported a net loss of $28.8 million in the fourth quarter of 2020, compared to a net loss of $56.8 million in the same period in 2019. The company's cash runway is expected to extend into the second quarter of 2023.

Wave Life Sciences reported a net loss of $33.1 million for the third quarter of 2020. The company's cash runway is expected to extend into the second quarter of 2023, bolstered by recent equity financing.

Wave Life Sciences reported a net loss of $40.5 million in the second quarter of 2020. The company's cash and cash equivalents totaled $94.1 million as of June 30, 2020. They anticipate funding operating and capital expenditure requirements into the fourth quarter of 2021.

Wave Life Sciences reported a net loss of $47.5 million in the first quarter of 2020, compared to a net loss of $44.2 million in the same period of 2019. The company's research and development expenses were $41.2 million, and general and administrative expenses were $13.0 million. Wave ended the quarter with $120.9 million in cash and cash equivalents.

Wave Life Sciences reported a net loss of $56.8 million in the fourth quarter of 2019, compared to a net loss of $37.9 million in the same period in 2018. The increase in net loss was primarily driven by increased research and development efforts and continued organizational growth.